# A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

> **NCT03984097** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 50 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** TAK-079
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT03984097
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-29
- **Primary completion:** 2026-03-25
- **Final completion:** 2026-03-25
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03984097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03984097, "A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03984097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*